No headlines found.
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Wed, 7-May 4:05 PM ET)
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
Globe Newswire (Wed, 30-Apr 7:00 AM ET)
Globe Newswire (Tue, 29-Apr 8:45 AM ET)
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
Globe Newswire (Mon, 28-Apr 7:00 AM ET)
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Adma Biologics trades on the NASDAQ stock market under the symbol ADMA.
As of July 17, 2025, ADMA stock price declined to $17.61 with 1,607,148 million shares trading.
ADMA has a beta of 0.89, meaning it tends to be less sensitive to market movements. ADMA has a correlation of 0.06 to the broad based SPY ETF.
ADMA has a market cap of $4.20 billion. This is considered a Mid Cap stock.
Last quarter Adma Biologics reported $115 million in Revenue and $.14 earnings per share. This fell short of revenue expectation by $-2 million and met earnings estimates .
In the last 3 years, ADMA traded as high as $25.67 and as low as $1.97.
The top ETF exchange traded funds that ADMA belongs to (by Net Assets): IJR, VTI, IWM, VXF, XBI.
ADMA has outperformed the market in the last year with a return of +28.3%, while the SPY ETF gained +12.4%. However, in the most recent history, ADMA shares have underperformed the stock market with its stock returning -17.1% in the last 3 month period and -2.9% for the last 2 week period, while SPY has returned +19.8% and +1.2%, respectively.
ADMA support price is $17.20 and resistance is $18.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADMA shares will trade within this expected range on the day.